Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. More Details
+ 3 more risks
Mediocre balance sheet and overvalued.
Share Price & News
How has Regulus Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RGLS's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RGLS underperformed the US Biotechs industry which returned 39.7% over the past year.
Return vs Market: RGLS underperformed the US Market which returned 17.2% over the past year.
Price Volatility Vs. Market
How volatile is Regulus Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StRegulus Therapeutics Inc. (NASDAQ:RGLS) Analysts Just Slashed This Year's Revenue Estimates By 25%
3 months ago | Simply Wall StNews Flash: Analysts Just Made A Upgrade To Their Regulus Therapeutics Inc. (NASDAQ:RGLS) Forecasts
8 months ago | Simply Wall StDid Changing Sentiment Drive Regulus Therapeutics's (NASDAQ:RGLS) Share Price Down A Disastrous 99%?
Is Regulus Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RGLS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RGLS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RGLS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: RGLS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RGLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RGLS is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (3.4x).
How is Regulus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RGLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RGLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RGLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RGLS's revenue is expected to decline over the next 3 years (-88.2% per year).
High Growth Revenue: RGLS's revenue is forecast to decline over the next 3 years (-88.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RGLS's Return on Equity is forecast to be high in 3 years time
How has Regulus Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RGLS is currently unprofitable.
Growing Profit Margin: RGLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RGLS is unprofitable, but has reduced losses over the past 5 years at a rate of 19.8% per year.
Accelerating Growth: Unable to compare RGLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RGLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: RGLS has a negative Return on Equity (-270.27%), as it is currently unprofitable.
How is Regulus Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: RGLS's short term assets ($28.6M) exceed its short term liabilities ($21.0M).
Long Term Liabilities: RGLS's short term assets ($28.6M) exceed its long term liabilities ($217.0K).
Debt to Equity History and Analysis
Debt Level: RGLS's debt to equity ratio (170.6%) is considered high.
Reducing Debt: Insufficient data to determine if RGLS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RGLS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RGLS has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.4% each year.
What is Regulus Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RGLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RGLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGLS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RGLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jay Hagan (51 yo)
Mr. Joseph P. Hagan, also known as Jay, has been the Chief Executive Officer, President and Director of Regulus Therapeutics Inc. since May 4, 2017 and served as its Interim Principal Financial Officer sin ...
CEO Compensation Analysis
Compensation vs Market: Jay's total compensation ($USD2.01M) is above average for companies of similar size in the US market ($USD598.77K).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||1.08yrs||US$506.91k||no data|
|Senior VP. General Counsel & Corporate Secretary||no data||US$787.91k||0.074% |
|Controller & Principal Accounting Officer||1.17yrs||no data||no data|
|Chief Scientific Officer||0.083yr||no data||no data|
|Senior Director of Corporate Development||no data||no data||no data|
Experienced Management: RGLS's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|Independent Director||7.42yrs||US$64.47k||0.44% |
|Member of the Scientific Advisory Board||1.5yrs||US$1.48m||no data|
|Independent Chairman of the Board||7.25yrs||US$84.98k||3.32% |
|Chairman of the Scientific Advisory Board & Independent Director||no data||US$59.72k||0.071% |
|Independent Director||1.25yrs||US$36.89k||0% |
|Member of the Scientific Advisory Board||no data||no data||no data|
|Member of the Scientific Advisory Board||no data||no data||no data|
|Independent Director||4.25yrs||US$57.34k||0.049% |
|Independent Director||2.42yrs||US$67.84k||0.086% |
|Independent Director||1.25yrs||US$21.10k||0% |
|Independent Director||3.25yrs||US$54.74k||0.11% |
Experienced Board: RGLS's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 72.5%.
Regulus Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Regulus Therapeutics Inc.
- Ticker: RGLS
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$18.464m
- Shares outstanding: 35.92m
- Website: https://www.regulusrx.com
Number of Employees
- Regulus Therapeutics Inc.
- 10614 Science Center Drive
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RGLS||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Oct 2012|
|7RG1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2012|
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/01 00:49|
|End of Day Share Price||2020/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.